TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04720456
Drug: SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles)
Normalized name: ULTRASOUND CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
Study: NCT04720456
Drug: SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)
Normalized name: ULTRASOUND CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
Study: NCT06704893
Drug: ASA injection 40 mg group
Normalized name: meningococcal group B vaccine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intra-articular knee injections under ultrasound guidance with AMNIOGEN® 40mg (HCT Regenerative, New Taipei, Taiwan) diluted in 3.0 mL of sterile normal saline.
Study: NCT06704893
Drug: ASA injection 20 mg group
Normalized name: meningococcal group B vaccine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intra-articular knee injections under ultrasound guidance with AMNIOGEN® 20mg (HCT Regenerative, New Taipei, Taiwan) diluted in 3.0 mL of sterile normal saline.
Study: NCT06704893
Drug: HA injection group
Normalized name: meningococcal group B vaccine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intra-articular knee injections under ultrasound guidance with 3 ml of HyLink (SEIKAGAKU CORPORATION, Tokyo, Japan).
Study: NCT06275919
Drug: Local Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this setting there are not drugs with indication. Every site will treat patients as per their experience.
Study: NCT05328557
Drug: CUG252
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUG252 will be administered by subcutaneous (SC) injection
Study: NCT05328557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by subcutaneous (SC) injection
Study: NCT05832229
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor) or matching placebo.
Study: NCT06342713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05470205
Drug: SHAPE measurement (Sonazoid ultrasoud contrast agent)
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
Study: NCT05470205
Drug: SHAPE measurement (Definity ultrasoud contrast agent)
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.
Study: NCT04989699
Drug: OTX-TKI/Sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTX-TKI is one dose so subsequent visits will be sham to maintain the mask
Study: NCT06704581
Drug: 5 mg BGM0504 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg BGM0504 injection administered subcutaneously (SC) once a week.
Study: NCT06704581
Drug: 15 mg BGM0504 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg BGM0504 injection administered subcutaneously (SC) once a week.
Study: NCT06704581
Drug: BGM0504 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGM0504 placebo administered SC once a week.
Study: NCT06056596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
Study: NCT05607030
Drug: SOC Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of at least 6 weeks of systemic antibiotics post-Stage 1 surgery followed by a 2-week antibiotic holiday before the Stage 2 surgery. After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.
Study: NCT05607030
Drug: Experimental Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.
Study: NCT06472583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,9% NaCl in the volume 100 ml
Study: NCT05925803
Drug: Placebo (blinded)
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo delivered subcutaneously, once weekly for 52 weeks
Study: NCT06507306
Drug: KQB198
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral KQB198
Study: NCT06229145
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT06290102
Drug: TEV-56248
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation
Study: NCT06160531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05188469
Drug: EG-COVID-003
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection
Study: NCT05188469
Drug: EG-COVID-001
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one, two or three single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection
Study: NCT05188469
Drug: A: EG-COVID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 0.5mL (mRNA 400μg)~Route of administration: Intramuscular injection
Study: NCT05188469
Drug: B: EG-COVID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive two single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 1mL (mRNA 800μg)~Route of administration: Intramuscular injection
Study: NCT05188469
Drug: C: EG-COVARo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVARo 0.5mL (mRNA 800μg)~Route of administration: Intramuscular injection
Study: NCT06034197
Drug: VGT-309
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.32mg/kg IV of VGT-309 given 12-36 hours before surgery
Study: NCT06467084
Drug: KVD900 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD900 Tablet 75 mg (1 x 75 mg)
Study: NCT06467084
Drug: KVD900 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD900 Tablet 150 mg (2 x 75 mg)
Study: NCT06467084
Drug: KVD900 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD900 Tablet 300 mg (1 x 300 mg)
Study: NCT04557462
Drug: LNP023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule 200 mg (b.i.d.) taken orally twice a day
Study: NCT06136741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous
Study: NCT05419011
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT04947553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, taken twice daily
Study: NCT04906213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10Mg Placebo Tab
Study: NCT05924243
Drug: RO7486967
Approvals — FDA: no, EMA: no, PMDA: no
Description: For up to approximately 28 days
Study: NCT05924243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For up to approximately 28 days
Study: NCT04880278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half of the participants (30 individuals) will receive placebo capsules that are opaque and contain only dextrose. Placebo capsules will be administered by mouth only once (around 120 minutes prior to fMRI scanning).
Study: NCT05650411
Drug: P2Y12 inhibitor-based SAPT after short DAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent P2Y12 inhibitor-based SAPT (ticagrelor 90 mg bd, or prasugrel 5 or 10 mg od, at the discretion of the investigator) during 2 years. Aspirin stopped after LMCA or at latest at hospital discharge.
Study: NCT05737615
Drug: hu5B1-TCO
Approvals — FDA: no, EMA: no, PMDA: no
Description: On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
Study: NCT06443645
Drug: Anthracycline
Normalized name: Anthracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: as standard of care
Study: NCT05222516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of Placebo capsules
Study: NCT06377761
Drug: Qishen Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: One package per time, twice a day, 90 days of treatment
Study: NCT06377761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One package per time, twice a day, 90 days of treatment (the placebo was basically the same as Qishen granules in terms of appearance, shape, color, taste, etc.)
Study: NCT05556512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06241118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study: NCT06241118
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical
Study: NCT05032157
Drug: LOU064 (blinded)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOU064 (blinded) active treatment
Study: NCT05032157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06781944
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants in the control arm will receive cyclical cyclophosphamide and glucocorticoids.~Oral cyclophosphamide will be given for 30 days in month 2, 4, 6.~The dosage is adjusted based on the age and renal function (rounded down to the nearest 25 mg, max 100 mg/day, Cyclophosphamide tablets should not be split; if necessary, alternating doses of 50 mg/day and 100 mg/day can be used):~* 2.0 mg/kg/d in patients \< 65 years with eGFR ≥60ml/min~* 1.5 mg/kg/d in patients \< 65 years with eGFR\<60ml/min~* 1.5 mg/kg/d in patients ≥ 65 years with eGFR ≥60ml/min~* 1.0 mg/kg/d in patients ≥ 65 years with eGFR\<60ml/min
Study: NCT06781944
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the control arm will receive cyclical cyclophosphamide and glucocorticoids.~Methylprednisolone 500 mg iv will be given for 3 consecutive days at the start of month 1,3,5 and followed by prednisone 0.5mg/kg/d (max 40mg/d) for 27 days.
Study: NCT06782048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo by mouth once each day for a total of 14 days.
Study: NCT06781086
Drug: AG regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 3 cycles of AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle).
Study: NCT05852002
Drug: 35 kDa hyaluronan fragment
Normalized name: PALMITOYL FRAGMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of 35kDa hyaluronan fragment was injected deeply into abdominal fat layer once a day for 28 consecutive days.
Study: NCT06781086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 3 cycles of neoadjuvant treatment with placebo (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant therapy (placebo 400 mg on days 1, 8, and 15 of a 21-day cycle).
Study: NCT06737406
Drug: Topical 5% fluorouracil cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% fluorouracil cream twice daily for 21 days on the affected area (palmoplantar)
Study: NCT06737406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo ointment in identical tubes in terms of color and scent and with identical usage instructions to calcipotriol.
Study: NCT06737406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo cream in identical tubes in terms of color and scent and with identical usage instructions to fluorouracil.
Study: NCT05110157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT04670081
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg, p.o.
Study: NCT06738368
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06738368
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given CIV
Study: NCT06587685
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel twice daily for 8 weeks
Study: NCT05306873
Drug: Placebo for Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily
Study: NCT05419583
Drug: Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin)
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy if atrial fibrillation identified (DOAC or Warfarin)
Study: NCT05419583
Drug: Guideline directed heart failure therapy
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of guideline approved heart failure treatments (ACE-inhibitor / angiotensin receptor blocker (ARB) / ARB and neprilysin inhibitor, mineralocorticoid receptor antagonist, beta blocker, SGLT-2 inhibitor, diuretic therapy)
Study: NCT05419583
Drug: Statins (Cardiovascular Agents)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins will be recommended for patients with coronary plaque disease or hypercholesterolaemia
Study: NCT05953389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of pitolisant tablets
Study: NCT05486715
Drug: Vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vit D
Study: NCT05206201
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two part study with single and multiple dose
Study: NCT05707403
Drug: BI 1015550 mixed with [C-14]-BI 1015550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment R
Study: NCT05176314
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered Orally.
Study: NCT05728489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04853368
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT05751421
Drug: Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution
Normalized name: Zynrelef (bupivacaine 60 MG / meloxicam 1.8 MG) per 2.3 ML Extended Release Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: zynrelef will be administered during surgery
Study: NCT02738073
Drug: Control: Saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04732494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.
Study: NCT04840914
Drug: LY3461767
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04840914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04455958
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05261321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control condition, the placebo will be administered to participants.
Study: NCT03770663
Drug: Cyclophosphamide and azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: European strategy 6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day
Study: NCT06195072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: see Experimental Arm intervention description
Study: NCT06582706
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: a readily available inert placebo will be used
Study: NCT04680273
Drug: [14C]-GDC-9545
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of \[14C\]-GDC-9545 capsule, 30 milligrams (mg) (not more than \[NMT\] 4.6 megabecquerel \[MBq\]; 124 microcurie \[μCi\]) with approximately 240 millilitres (mL) water in the fasted state.
Study: NCT06480981
Drug: Noribogaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noribogaine capsules
Study: NCT06245941
Drug: TQ05105 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor
Study: NCT06245941
Drug: TQB3909 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.
Study: NCT04971161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One topical application with a syringe
Study: NCT05704829
Drug: Standard-of-Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy+T+P
Study: NCT05621070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered per auto-injector. Participants will receive placebo every 2 weeks subcutaneously.
Study: NCT05621070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered per auto-injector. Participants will receive placebo every 4 weeks subcutaneously.
Study: NCT05684055
Drug: First-line antihypertensive single-pill combination (SPC)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In intervention villages, participants diagnosed with aHT are offered pharmacological treatment (eHealth supported prescription of first-line antihypertensive single-pill combination (SPC)) and treatment monitoring in the villages by CC-VHWs guided by the ComBaCaL app.
Study: NCT05156047
Drug: Double-blind placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
Study: NCT06424756
Drug: MitoTempo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During each experimental visit, intradermal microdialysis will be used to locally infuse MitoTempo (a mitochondria-specific superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
Study: NCT05548556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)
Study: NCT05466890
Drug: PL8177 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.
Study: NCT05466890
Drug: PL8177
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 3/4 of randomized patients will receive active PL8177.
Study: NCT04868760
Drug: IBI310
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
Study: NCT05993806
Drug: L04RD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of L04RD1
Study: NCT05993806
Drug: L04TD3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of L04TD3
Study: NCT06789744
Drug: Intravenous Patient-Controlled Analgesia (PCA) (fentanyl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For intravenous PCA, a solution of fentanyl 2 mcg/kg will be diluted to a total volume of 100 mL with normal saline. The PCA settings will be as follows: a basal rate of 2 mL/hour, a PCA dose of 2 mL, and a lockout interval of 15 minutes.
Study: NCT05773937
Drug: 9MW2821
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).